CN111455058A - Tumor marker related to breast cancer tumor, application and kit - Google Patents
Tumor marker related to breast cancer tumor, application and kit Download PDFInfo
- Publication number
- CN111455058A CN111455058A CN202010463667.0A CN202010463667A CN111455058A CN 111455058 A CN111455058 A CN 111455058A CN 202010463667 A CN202010463667 A CN 202010463667A CN 111455058 A CN111455058 A CN 111455058A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- tumor
- phf20
- kit
- tumor marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 76
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 76
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 58
- 239000000439 tumor marker Substances 0.000 title claims abstract description 18
- 101001071230 Homo sapiens PHD finger protein 20 Proteins 0.000 claims abstract description 50
- 102100036878 PHD finger protein 20 Human genes 0.000 claims abstract description 50
- 238000003745 diagnosis Methods 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 16
- 238000004393 prognosis Methods 0.000 claims abstract description 15
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 15
- 238000003753 real-time PCR Methods 0.000 claims description 14
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 108010033040 Histones Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 239000003596 drug target Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 230000002222 downregulating effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000012226 gene silencing method Methods 0.000 abstract description 2
- 102000009331 Homeodomain Proteins Human genes 0.000 abstract 1
- 108010048671 Homeodomain Proteins Proteins 0.000 abstract 1
- 108091027967 Small hairpin RNA Proteins 0.000 abstract 1
- 102100028370 Zinc finger protein 20 Human genes 0.000 abstract 1
- 101710160497 Zinc finger protein 20 Proteins 0.000 abstract 1
- 230000033228 biological regulation Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011160 research Methods 0.000 abstract 1
- 239000004055 small Interfering RNA Substances 0.000 abstract 1
- 230000005740 tumor formation Effects 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 16
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 10
- 101100029612 Homo sapiens PHF20 gene Proteins 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229960001701 chloroform Drugs 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000030776 invasive breast carcinoma Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- AWXGSYPUMWKTBR-UHFFFAOYSA-N 4-carbazol-9-yl-n,n-bis(4-carbazol-9-ylphenyl)aniline Chemical compound C12=CC=CC=C2C2=CC=CC=C2N1C1=CC=C(N(C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=2C=CC(=CC=2)N2C3=CC=CC=C3C3=CC=CC=C32)C=C1 AWXGSYPUMWKTBR-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000837344 Homo sapiens T-cell leukemia translocation-altered gene protein Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100028692 T-cell leukemia translocation-altered gene protein Human genes 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a tumor marker related to breast cancer tumor, application and a kit, and relates to the technical field of tumor molecular diagnosis. The inventor researches and discovers that the plant homeodomain zinc finger protein 20(PHF20) is highly expressed in breast cancer. After the shRNA gene silencing method is used for down-regulating the gene, the gene has obvious inhibiting effect on the tumor formation of the breast cancer cells. This suggests that PHF20 can be a target for drug regulation in addition to being a breast cancer marker. The invention provides a new biomarker for treating and diagnosing breast cancer. The PHF20 serving as a tumor marker of the breast cancer can be used for preparing a kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of the breast cancer, and has important clinical application value.
Description
Technical Field
The invention relates to the technical field of tumor molecular diagnosis, in particular to a tumor marker related to breast cancer tumor, application and a kit.
Background
Breast cancer is one of the common malignancies in women, with about 11% of women in western countries such as the united states suffering from breast cancer. In China, with the expansion of urbanization and the change of life style, breast cancer patients are rapidly increased at a speed of 160 ten thousand per year, and the number of the patients dying from breast cancer is up to 120 thousand per year.
The main cause of death of breast cancer patients after treatment is drug resistance and metastasis of the tumor, while cancer stem cells have the characteristics of resistance to radiotherapy and chemotherapy and are therefore considered to be the root cause of failure of the treatment regimen due to drug resistance and metastasis of the tumor. Traditional radiotherapy and treatment approaches have been shown to result in the enrichment of breast cancer stem cells in tumors. The new treatment regimens are: according to the marker characteristics of the tumor stem cells, the cancer stem cells are eliminated in a targeted mode, and the signal transduction pathway of the canceration of the breast stem cells is inhibited. However, the existing targeted therapy aiming at markers and signal paths related to breast cancer stem cells has problems: no specific breast cancer stem cell marker with therapeutic value is found at present; signal transduction pathways are also expressed in normal cells, and drugs that inhibit the pathways have also been reported to have serious side effects.
Therefore, it is valuable to find more specific molecular events, and thus provide new strategies for the treatment of breast cancer.
Disclosure of Invention
The invention aims to overcome the defects and shortcomings of the prior art, provides a tumor marker related to breast cancer tumor, and provides a new target for treating breast cancer tumor.
The invention also aims to use the tumor marker in preparing a preparation or a kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of breast cancer tumors.
In order to solve the above problems, the present invention proposes the following technical solutions:
the invention provides application of a tumor marker PHF20 as a tumor marker related to breast cancer tumor. The sequence of PHF20 is shown in SEQ ID NO. 5.
In one aspect, the tumor marker associated with breast cancer tumor provided by the invention is PHF20, is one of the constituent proteins of MOF complex, and can identify the dimethylated histone lysine site through Tudor region.
The inventor creatively discovers the relationship between the PHF20 gene and breast cancer through analysis and verification of experimental data, and the PHF20 is expected to be a marker for diagnosis and prognosis judgment of breast cancer tumors, thereby providing a new target for treatment of the breast cancer tumors. Therefore, the PHF20 can be used for preparing auxiliary diagnosis, curative effect prediction and prognosis judgment preparations for breast cancer tumors, and can also be used for preparing auxiliary diagnosis, curative effect prediction and prognosis judgment kits for breast cancer tumors.
The invention also provides a kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of breast cancer, which comprises a specific primer of PHF20 and a specific primer of a reference gene GAPDH. The sequence of the specific upstream primer of PHF20 is shown as SEQ ID NO.1, the sequence of the specific downstream primer of PHF20 is shown as SEQ ID NO.2, the sequence of the specific upstream primer of GAPDH is shown as SEQ ID NO.3, and the sequence of the specific downstream primer of GAPDH is shown as SEQ ID NO. 4.
The kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of breast cancer provided by the invention is a real-time fluorescence quantitative PCR detection kit. Specific primers of PHF20 and reference gene GAPDH are suitable for detecting SYBR Green. In addition, the kit also comprises a standard DNA template and a PCR reaction system, wherein the PCR reaction solution in the PCR reaction system is real-time fluorescent quantitative PCR reaction solution and further comprises fluorescent dye. The real-time fluorescent quantitative PCR reaction solution comprises dNTP, Mg2+, Taq enzyme and buffer solution, wherein the fluorescent dye is SYBR Green II, and the Taq enzyme is hot-start enzyme.
The invention also provides a method for detecting PHF20 by using the kit, which comprises the following steps:
1) extracting total RNA of the sample;
2) preparing sample cDNA;
3) PHF20 was quantitatively amplified.
The invention is further illustrated below:
PHF20 is located on chromosome 20 chr20:35771974-35950381, and can be applied to a kit for assisting breast cancer tumor diagnosis.
The real-time fluorescent quantitative PCR detection kit provided by the invention is used for detecting the PHF20 expression levels in the breast cancer tumor of a randomly extracted breast cancer tumor patient and the paired normal breast tissue, and the PHF20 is found to have differential expression in the breast cancer tumor tissue and the paired normal breast tissue and has high expression in the breast cancer tumor tissue. The above results indicate that PHF20 may be a novel diagnostic marker for breast cancer tumors.
The kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of the breast cancer tumor comprises:
(1) extracting total RNA from breast cancer tumor tissue with Trizol reagent, chloroform, isopropanol, 75% ethanol, and enzyme-free water;
(2) reagents for reverse transcription of total RNA into cDNA, including reverse transcription buffer, magnesium chloride, deoxynucleotide triphosphate base, RNase inhibitor, MM L V reverse transcriptase and random primer;
(3) the reagents required by the real-time fluorescence quantitative PCR of cDNA comprise PHF20 real-time fluorescence quantitative PCR specific primers, GAPDH internal reference specific PCR primers, real-time fluorescence quantitative SYBR dye and no enzyme water, wherein the PHF20 specific PCR primers comprise ① PHF20 upstream primer (SEQ ID NO.1) ② PHF 20-downstream primer (SEQ ID NO.2), and the GAPDH internal reference specific PCR primers comprise ① GAPDH upstream primer (SEQ ID NO.3) ② GAPDH downstream primer (SEQ ID NO. 4).
The invention discovers and proves that the PHF20 gene has high expression in histiocyte of breast cancer tumor, and can be used as a novel breast cancer tumor diagnosis marker or a drug target. The invention provides a powerful molecular biology tool for the auxiliary diagnosis of breast cancer tumors, and has profound clinical significance and important popularization and application prospects.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the description of the embodiments are briefly introduced below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without creative efforts.
FIG. 1 shows the effect of PHF20 expression on patient survival time;
FIG. 2 shows the expression difference of PHF20 in normal breast tissue, breast cancer tissue and invasive breast cancer;
FIG. 3 shows the difference in expression of PHF20 in breast cancer cell lines MCF-7, HTB21, MDA231, HTB23, HTB25, HTB27, HTB123, MDA-MB-436, HTB123, MDA-MB-453, HTB123, MDA-MB-468 versus PBMC cells, MCF-10A cells;
FIG. 4 shows the effect of the knockout of PHF20 gene on breast cancer HTB21 cells and MDA-MB-231 cells (A) and on in vitro neoplasia (B).
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments. It is apparent that the embodiments to be described below are only a part of the embodiments of the present invention, and not all of them. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1: comparison of the relationship between PHF20 Gene expression and survival Rate in Breast cancer patients
In order to understand the expression of PHF20 in the tumor tissue of breast cancer patients and the correlation between the expression level and survival time, we analyzed the expression level of PHF20mRNA in the tumor samples of 302 breast cancer patients in the TCTA database, and we divided the patients into patients with high expression of PHF20 (42) and patients with low expression of PHF20 (260) according to the mean value of the expression level of PHF20 of all the patients as the demarcation point, and found that the higher the expression level of PHF20 is, the shorter the survival time of the patients is, both are negative correlation (FIG. 1) in combination with the follow-up data of the patients, and the above results suggest that PHF20 can be used as an index for evaluating the prognosis of the patients.
Example 2: the kit for auxiliary diagnosis, curative effect prediction and prognosis of breast cancer tumors provided by the invention is used for detecting the expression of the PHF20 gene in normal breast tissues, breast cancer tissues and invasive breast cancers.
Wherein, the kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of the breast cancer tumor comprises:
(1) the reagent for extracting total RNA from breast cancer tumor comprises Trizol reagent, chloroform, isopropanol and DEPC water.
(2) Reagents for reverse transcription of total RNA into cDNA: a promega reverse transcription kit (GoScript TMReverse Transcriptase, A5003) comprises GoScript TM5X Reaction Buffer, MgCl2, PCR NucleotideMix, Recombinant Ribonuclense Inhibitor, GoScript TMReverse Transcriptase, Nuclear-Free Water.
(3) The reagents used for real-time fluorescence quantitative PCR of cDNA comprise PHF 20-specific primers for real-time fluorescence quantitative PCR, specific primers for GAPDH internal reference, real-time fluorescence quantitative SYBR dye (Roche 4887352001L htCycler480SYBRGreen I Master) and DEPC water, wherein the sequences of the primers for fluorescence quantitative PCR are shown in Table 1.
TABLE 1 primer sequences for real-time fluorescent quantitative PCR of cDNA
Numbering | Primer name | Sequence of |
SEQ ID NO 1 | PHF20 Forward Primer | GAATCAGCTTTGAAGTGGGAGC |
SEQ ID NO 2 | PHF20 Reverse Primer | GTTCCAACGCTTGAAATGGATG |
SEQ ID NO 3 | GAPDH Forward Primer | GGAGCGAGATCCCTCCAAAAT |
SEQ ID NO 4 | GAPDH Reverse Primer | GGCTGTTGTCATACTTCTCATGG |
The specific detection method comprises the following steps:
1: extracting total RNA of breast cancer tumor and matched normal breast tissue.
(1) Fresh or frozen at-80 deg.C about 20mg, adding 1ml Trizol ice, grinding, cutting tissue with scissors, adding 400ul Trizol to prevent overflow, grinding thoroughly, and filling to 1 ml. Standing at room temperature for 5-10 min.
(2) Trizol and trichloromethane according to the volume ratio of 5: 1, adding Trizol into trichloromethane, carrying out vortex oscillation for 30s, standing at room temperature for 5min, and centrifuging at 12000g and 4 ℃ for 15 min.
(3) Sucking about 400ul of supernatant, taking care to avoid sucking intermediate solid layer, adding 400ul of isopropanol, mixing up and down, standing at room temperature for 10min without vigorous shaking, and centrifuging at 12000g speed at 4 deg.C for 10 min.
(4) The supernatant was aspirated, 1ml of 75% strength ethanol prepared with DEPC was added, the precipitate was gently knocked off on a laboratory bench, and centrifuged at 7500g at 4 ℃ for 5 min.
(5) Absorbing supernatant, standing at room temperature for 5-10min, adding PEPC water of about 70 deg.C to dissolve RNA, and storing at-80 deg.C.
(6) Mixing with 1% agarose gel, adding 1ul 6X L loading Buffer into 1ug RNA, performing electrophoresis for about 20min, storing by gel electrophoresis imaging system, and analyzing.
(7) And (3) detecting the concentration and purity of the RNA by using the Nano Drop, adjusting zero by using DEPC water, fully and uniformly mixing the RNA sample, dripping 2ul of the sample on a Nano Drop detection probe, placing a measuring arm, measuring the concentration of the RNA, and recording the ratio of 260/280.
2: the total RNA extracted in step 1 is reversely transcribed into cDNA, and the expression level of PHF20 is detected by real-time fluorescent quantitative PCR.
(1) Reverse transcription of total RNA to cDNA Promega reverse transcription kit was used.
The following system is configured:
system I: 2ug of RNA was dissolved in DEPC water, and 1ul of random primer was added to make up to 10 ul. The mixture was placed on a PCR instrument at 70 ℃ for 5 minutes and immediately ice-cooled for 5 minutes.
The components in system II are shown in table 2:
table 2:
system I and system II were mixed, centrifuged instantaneously and placed in a PCR instrument with the program parameters shown in Table 3.
TABLE 3
Step1 | Step2 | Step3 | Step4 | |
Temperature of | 25 |
42℃ | 75℃ | 4℃ |
Time of day | 5min | 1h | 15min | ∞ |
(2) Real-time fluorescent quantitative PCR was performed using the Roche L ightCycler480SYBRGreenI Master kit.
The reaction system is shown in the following table 4:
table 4:
name (R) | Volume of |
cDNA | 1ul |
DEPCE water | 1ul |
Upstream primer | 1ul |
Downstream primer | 1ul |
SYBR GREEN | 10ul |
The instrument adopts Roche 480, and the real-time fluorescent quantitative PCR program is as follows: pre-denaturation at 95 ℃ for 10min, followed by 40 cycles: 95 ℃ for 10s, 60 ℃ for 20s and 72 ℃ for 30 s.
The experimental data adopts a relatively quantitative analysis method, GAPDH is used as an internal reference gene, and the calculation formula is as follows:
ΔCT=ΔCT-ΔCTGAPDH
Δ Δ CT ═ Δ C cancer tissue- Δ C normal tissue
Relative expression quantity log 2-delta CT
The relative expression of real-time fluorescent quantitative PCR PHF20 was analyzed by software SPSS 18.0.
As a result: the PHF20 expression was significantly increased in breast cancer tumor tissues compared to paired normal tissues, as shown in fig. 2.
Example 3: the kit for auxiliary diagnosis, curative effect prediction and prognosis of breast cancer tumors provided by the invention is used for detecting the expression of the PHF20 gene in different breast cancer cell lines.
Detecting the expression state of PHF20 in different cells, wherein the breast cancer cells are MCF-7, HTB21, MDA231, HTB23, HTB25, HTB27, HTB123, MDA-MB-436, HTB123, MDA-MB-453, HTB123 and MDA-MB-468; the normal cells are: PBMC and MCF-10A.
The procedure was as in example 2.
And (3) detection results: referring to fig. 3, it can be seen that 12 breast cancer cells all showed high expression of PHF20 compared to normal cells, and this expression difference can be used as a reference for judging breast cancer tumors.
Example 4: analysis of PHF20 expression in relation to clinical characteristics of cases
The total cases were ranked from low to high according to the relative expression value 2- Δ Δ CT of PHF20 in breast cancer and paired normal tissues, and 32 cases before and after the ranking were divided into low expression group and high expression group. Based on the above grouping, the relationship between the expression level of the target PHF20 and the sex, age, lesion site, tumor size, differentiation grade, lymph node metastasis and TNM stage of the case was analyzed. From the P values, PHF20 high expression in breast cancer was statistically not different from breast tumor age, sex, lesion site, tumor size, N grade, TNM grade, lymph node invasion, distant metastasis, but closely related to tumor differentiation degree, T grade, see table 5.
TABLE 5PHF20 clinical information Table
Example 5
The effect of the PHF20 gene on the growth of breast cancer HTB21 cells and MDA-MB-231 cells and on in vitro neoplasia was examined.
Experimental method to study the effect of PHF20 on tumorigenicity of breast cancer, we first constructed HTB21 cells and MDA-MB-231 cells with PHF20 gene silencing (PHF20 KD). by culturing HTB21 cells or MDA-MB-231 cells in T25 culture flasks, 5m L virus solution and 5 mu L polybrene capable of expressing PHF20shRNA were added when the cell density was 50% -60%, and the mixture was placed at 37 ℃ and 5% CO2Culturing in constant temperature incubator for 6 hr, discarding culture solution mixed with virus solution, changing into complete culture medium, placing at 37 deg.C and 5% CO2Culturing in a constant temperature incubator. HTB21 cells and MDA-MB-231 cells with PHF20 gene silenced (PHF20KD) are obtained by puromycin screening.
Next, we cultured wild-type (control) and PHF20KD cells in mmospere serum-free suspension medium and in low adhesion 96-well plates for suspension spheronization, observed under a microscope and photographed 7 days later (panel a of fig. 4), counted and statistically shown to significantly inhibit the tumorigenic capacity of breast cancer cells after down-regulating their expression by PHF20 silencing.
Finally, we placed 5-week-old female Balb/c nude mice in individually ventilated SPF-grade micro-isolator cages each mouse was injected subcutaneously on the right side with 10 μ L in PBS6After that, the size of the tumor was measured periodically with a caliper every 2 days by measuring the length and width of the tumor, the tumor volume was calculated as volume (mm3) ═ length × width × width/2 after the mice were sacrificed, the transplanted tumor was taken out for photographing and weighing, and as a result, it was found that the tumorigenic ability of PHF20KD MDA-MB-231 cells in the immunodeficient mice was significantly weaker than that of the control group (part B of fig. 4).
The results of the experiment are shown in FIG. 4.
The results show that PHF20 can be used as a novel molecular marker for assisting breast cancer tumor diagnosis. Provides a powerful molecular biology tool for the auxiliary diagnosis of the breast cancer, and has profound clinical significance and important popularization and application prospects.
In the above embodiments, the descriptions of the respective embodiments have respective emphasis, and for parts that are not described in detail in a certain embodiment, reference may be made to related descriptions of other embodiments.
While the invention has been described with reference to specific embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Sequence listing
<110> Shenzhen Shennuo Shineno Hospital, Shenzhen Shennuo Immunity Co., Ltd
<120> tumor marker related to breast cancer tumor, application and kit
<130>0429
<141>2020-05-27
<160>5
<170>SIPOSequenceListing 1.0
<210>1
<211>22
<212>DNA
<213> Artificial sequence (artificial)
<400>1
gaatcagctt tgaagtggga gc 22
<210>2
<211>22
<212>DNA
<213> Artificial sequence (artificial)
<400>2
gttccaacgc ttgaaatgga tg 22
<210>3
<211>21
<212>DNA
<213> Artificial sequence (artificial)
<400>3
ggagcgagat ccctccaaaa t 21
<210>4
<211>23
<212>DNA
<213> Artificial sequence (artificial)
<400>4
ggctgttgtc atacttctca tgg 23
<210>5
<211>3039
<212>DNA
<213> human (Homo sapiens)
<400>5
atgacaaagc atccacctaa cagacgagga atcagctttg aagtgggagc ccagttggaa 60
gcccgggacc gtttaaaaaa ctggtatcca gctcacatag aagacattga ctacgaggaa 120
ggaaaagtac tcatccattt caagcgttgg aaccatcgtt atgatgagtg gttctgctgg 180
gacagtcctt atttacgccc tttagagaaa atacagctga ggaaagaggg cttgcatgaa 240
gaggatggat cttctgaatt tcaaataaat gagcaggtcc ttgcttgctg gtctgattgt 300
cgtttttacc cggccaaagt cactgctgtt aacaaggatg gtacttacac tgtgaaattt 360
tatgatggag tagttcagac tgtcaaacat attcatgtca aagctttttc caaagatcag 420
aatattgtgg gtaatgctag gcctaaagaa acagatcaca aaagtctttc atcatctcct 480
gataaacgag agaagtttaa agaacagaga aaagcaacag tgaatgtgaa gaaagacaaa 540
gaagataaac ccttaaagac agaaaagcga cccaagcagc ctgataaaga aggaaagtta 600
atctgttctg aaaaggggaa agtgtcagag aaaagtcttc ccaagaacga gaaggaagac 660
aaggaaaaca tttccgaaaa tgacagagag tattctggag atgcccaagt ggataagaaa 720
cctgaaaatg acattgtgaa gagtccacaa gaaaacttga gggaacccaa aagaaaacga 780
ggcagacccc cttccatagc tcctactgct gtggattcaa actctcaaac tttgcaacca 840
ataacattgg aactgagaag aaggaaaata tcaaaaggat gtgaagtccc attaaaacgt 900
cctcggcttg acaaaaattc atcccaggaa aagtcaaaaa actactcgga aaacactgac 960
aaagacttat cgaggagacg ttcctccagg ctgtccacta atgggaccca tgagatccta 1020
gatcctgact tggttgtatc agatttggtt gatacggatc ctttgcaaga cacgttgtct 1080
agtaccaagg aatctgaaga aggtcagttg aagtctgctt tggaagctgg ccaggtctca 1140
tctgcactga cttgccactc ctttggggat ggatccgggg ctgcaggctt ggagttgaac 1200
tgcccatcaa tgggagaaaa cacgatgaaa acagaaccga cttctcccct tgtggaatta 1260
caagagattt cgactgtgga agtaacaaat acttttaaga aaacagatga ttttgggtca 1320
tctaatgcac cagctgtcga cctagaccat aagtttagat gcaaagttgt ggactgttta 1380
aaatttttcc gcaaagccaa actgttgcac tatcacatga agtatttcca tggaatggag 1440
aagtcactgg agccagaaga gagcccggga aagaggcatg tccaaaccag gggcccttca 1500
gcttcagaca agcccagcca ggagaccctg accaggaagc gggtctctgc cagttcccca 1560
actacaaaag acaaggaaaa gaataaagag aagaaattca aggagtttgt gagagtgaag 1620
ccaaagaaga aaaagaaaaa gaaaaagaaa accaaacctg aatgcccctg cagtgaggag1680
atcagtgaca cctcccagga accttctcca cccaaggcat ttgctgttac caggtgtggg 1740
tcctcacaca agccaggggt ccatatgagc ccgcagcttc atggcccaga atctggacac 1800
cacaaaggga aagtgaaagc attggaggag gataatttga gtgagtcctc ttctgagagc 1860
tttctctgga gtgatgatga gtatggccaa gatgtggatg tgaccaccaa cccagatgag 1920
gaacttgatg gggatgaccg ctatgacttc gaggtggtcc gctgcatctg tgaggtccag 1980
gaggaaaatg acttcatgat tcagtgtgaa gagtgccagt gctggcagca tggggtctgc 2040
atgggattac tggaagaaaa tgtgcccgag aaatacacct gttatgtttg ccaagaccct 2100
ccaggtcaga ggcctggctt caagtactgg tatgacaagg agtggctgag caggggacat 2160
atgcatggcc tggcatttct agaagagaac tactcccatc agaatgccaa gaagatcgtg 2220
gccacccacc agcttcttgg tgatgtgcag agagtgattg aggttctgca tggcctgcag 2280
ctcaagatga gcatcttgca aagccgggag catcctgatc tgccgctgtg gtgccagcct 2340
tggaaacagc actcagggga ggggagatct catttcagaa acatccctgt cactgacacc 2400
aggagcaagg aggaagctcc aagctataga actttgaacg gggcagtgga gaagcccagg 2460
cccctggccc tgcccctgcc gcgttctgtg gaggaatcct atatcaccag tgagcattgc 2520
taccagaagc cccgcgccta ttaccctgcc gtggagcaga agctggtggt ggagacgagg 2580
ggctctgccc tcgacgatgc ggtcaacccc ctccatgaga acggcgatga ttccctttcc 2640
ccgcgcctgg gctggcctct agaccaagac aggagcaagg gggacagtga ccccaaaccc 2700
ggctccccaa aggtgaagga atatgtctcc aaaaaggccc taccagaaga agcccctgct 2760
cggaagctgc tggacagagg tggagagggg ctgctgagct cccagcacca gtggcagttt 2820
aacctgctga cccatgtgga atctcttcag gatgaagtta cgcacaggat ggactccatt 2880
gagaaggagt tggatgtgtt ggagagctgg ctggactaca ctggggaact ggagccccct 2940
gagccgctgg ccaggcttcc gcagctcaag cattgtatca agcagctgct gatggacctg 3000
ggcaaggtgc agcagatcgc cctctgctgc tcaacatga 3039
Claims (10)
1. Use of a tumor marker PHF20 as a tumor marker associated with a breast cancer tumor.
2. A tumor marker associated with a breast cancer tumor, wherein the tumor marker is PHF20, and recognizes a dimethylated histone lysine site through its Tudor region.
3. The use of the tumor marker associated with breast cancer tumor of claim 2 in the preparation of a preparation for the auxiliary diagnosis, prediction of therapeutic effect and prognosis of breast cancer.
4. The use of the tumor marker associated with breast cancer tumor of claim 2 in the preparation of a kit for the auxiliary diagnosis, efficacy prediction and prognosis of breast cancer.
5. A kit for auxiliary diagnosis, curative effect prediction and prognosis judgment of breast cancer is characterized by comprising specific primers of PHF 20.
6. The kit of claim 5, wherein the sequence of the specific upstream primer of PHF20 is shown as SEQ ID No.1, and the sequence of the specific downstream primer of PHF20 is shown as SEQ ID No. 2.
7. The kit of claim 5, further comprising primers specific for the reference gene GAPDH.
8. The kit of claim 7, wherein the sequence of the specific upstream primer of the reference gene GAPDH is shown as SEQ ID NO.3, and the sequence of the specific downstream primer of the reference gene GAPDH is shown as SEQ ID NO. 4.
9. The kit of claim 7, wherein the kit is a real-time fluorescent quantitative PCR detection kit.
10. The use of PHF20 as defined in claim 1 as a drug target for breast cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010463667.0A CN111455058A (en) | 2020-05-27 | 2020-05-27 | Tumor marker related to breast cancer tumor, application and kit |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010463667.0A CN111455058A (en) | 2020-05-27 | 2020-05-27 | Tumor marker related to breast cancer tumor, application and kit |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111455058A true CN111455058A (en) | 2020-07-28 |
Family
ID=71679646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010463667.0A Pending CN111455058A (en) | 2020-05-27 | 2020-05-27 | Tumor marker related to breast cancer tumor, application and kit |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111455058A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112159848A (en) * | 2020-09-30 | 2021-01-01 | 长治医学院 | Application of cyclic RNA as gastric cancer diagnosis biomarker and prognosis evaluation reagent |
CN114292919A (en) * | 2022-01-11 | 2022-04-08 | 广东省人民医院 | Early Luminal breast cancer risk diagnosis kit |
WO2022142677A1 (en) * | 2020-12-30 | 2022-07-07 | 上海奕谱生物科技有限公司 | Tumor marker and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101283106A (en) * | 2005-07-27 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | Method of diagnosing small cell lung cancer |
US20150038351A1 (en) * | 2012-09-11 | 2015-02-05 | The Regents Of The University Of California | Gene Signatures That Predispose Or Protect Individuals From Low-Dose Radiation Induced Breast Cancer Or Are Associated with Disease-Free Survival |
CN105228640A (en) * | 2013-02-26 | 2016-01-06 | 王荣福 | PHF20 and JMJD3 compositions and the using method in immunotherapy of tumors thereof |
CN106498062A (en) * | 2016-11-04 | 2017-03-15 | 邱宾涛 | A kind of product of diagnosis of prostate cancer and its application |
KR20170109340A (en) * | 2016-03-21 | 2017-09-29 | 충남대학교산학협력단 | Method of providing information for cancer cell using PHF20 |
CN107937526A (en) * | 2017-12-26 | 2018-04-20 | 徐州维康生物科技有限公司 | A kind of relevant tumor markers of neuroblastoma and its application |
CN110354279A (en) * | 2018-04-09 | 2019-10-22 | 湖南师范大学 | Application of the tumor suppressor gene ZCCHC10 in pulmonary cancer diagnosis and Index for diagnosis and therapeutic agent |
-
2020
- 2020-05-27 CN CN202010463667.0A patent/CN111455058A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101283106A (en) * | 2005-07-27 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | Method of diagnosing small cell lung cancer |
US20150038351A1 (en) * | 2012-09-11 | 2015-02-05 | The Regents Of The University Of California | Gene Signatures That Predispose Or Protect Individuals From Low-Dose Radiation Induced Breast Cancer Or Are Associated with Disease-Free Survival |
CN105228640A (en) * | 2013-02-26 | 2016-01-06 | 王荣福 | PHF20 and JMJD3 compositions and the using method in immunotherapy of tumors thereof |
KR20170109340A (en) * | 2016-03-21 | 2017-09-29 | 충남대학교산학협력단 | Method of providing information for cancer cell using PHF20 |
CN106498062A (en) * | 2016-11-04 | 2017-03-15 | 邱宾涛 | A kind of product of diagnosis of prostate cancer and its application |
CN107937526A (en) * | 2017-12-26 | 2018-04-20 | 徐州维康生物科技有限公司 | A kind of relevant tumor markers of neuroblastoma and its application |
CN110354279A (en) * | 2018-04-09 | 2019-10-22 | 湖南师范大学 | Application of the tumor suppressor gene ZCCHC10 in pulmonary cancer diagnosis and Index for diagnosis and therapeutic agent |
Non-Patent Citations (5)
Title |
---|
JING XUN ET AL: "JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity", 《ONCOTARGET》 * |
XI ZHANG ET AL: "G9a-mediated methylation of ERa links the PHF20/MOF histone acetyltransferase complex to hormonal gene expression", 《NATURE COMMUNICATIONS》 * |
夏邦顺 何蕴韶主编: "《临床分子诊断学》", 31 July 2012, 中山大学出版社 * |
孙干成 等: "PHF20相互作用蛋白质组学分析及其在肿瘤中的作用研究", 《天津医科大学学报》 * |
孙干成: "PHF20相互作用蛋白质组学分析及其在肿瘤中的作用研究", 《万方学位论文》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112159848A (en) * | 2020-09-30 | 2021-01-01 | 长治医学院 | Application of cyclic RNA as gastric cancer diagnosis biomarker and prognosis evaluation reagent |
WO2022142677A1 (en) * | 2020-12-30 | 2022-07-07 | 上海奕谱生物科技有限公司 | Tumor marker and application thereof |
CN114292919A (en) * | 2022-01-11 | 2022-04-08 | 广东省人民医院 | Early Luminal breast cancer risk diagnosis kit |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111455058A (en) | Tumor marker related to breast cancer tumor, application and kit | |
CN111778338B (en) | Application of circular RNA biomarker | |
CN108342482B (en) | Glioblastoma marker, application thereof and kit | |
EP3369826A1 (en) | Biomarker microrna for prediction of prognosis of head and neck cancer | |
CN108949990A (en) | A kind of kit and method detecting EGFR genetic mutation | |
CN110616229A (en) | Fusion gene of FGFR1 translocation blood disease and detection primer and application thereof | |
CN109593848A (en) | A kind of tumour correlated series, long-chain non-coding RNA and its application | |
CN107937526B (en) | Tumor marker related to neuroblastoma and application thereof | |
CN108456733A (en) | Pancreatic duct adenocarcinoma marker and application thereof | |
CN107475441B (en) | Biomarker for predicting responsiveness of breast cancer patient to AT regimen neoadjuvant chemotherapy | |
CN107475386B (en) | Long-chain non-coding RNA marker for diagnosis and treatment osteosarcoma | |
CN112195248A (en) | Application of lncRNA DLEU1 as glioma temozolomide drug resistance detection, treatment and prognosis molecular target | |
CN110241199A (en) | MiR-584-5p is as the application in acute respiratory distress syndrome biomarker | |
CN110331207A (en) | Adenocarcinoma of lung biomarker and related application | |
CN109486817A (en) | A kind of application of the long-chain non-coding RNA and combinations thereof in diagnoses and treatment cholangiocarcinoma | |
CN109082468A (en) | Detect the kit and method of 19 exons mutation of EGFR gene | |
CN111575374B (en) | Molecular marker for early pancreatic tumor detection, detection method and application thereof | |
CN105753960B (en) | A kind of tumor markers and its application | |
CN111808946B (en) | Myelodysplastic syndrome marker and kit thereof | |
CN103451303B (en) | Kit for detecting expression level of human ERCC1 (excision repair cross complementation 1) through PCR (polymerase chain reaction) method | |
CN113637750A (en) | Auxiliary diagnosis, prognosis diagnosis or risk stratification marker for acute myeloid leukemia and application thereof | |
CN103180461A (en) | Compositions and methods for prognosis of mesothelioma | |
CN110468134A (en) | One kind tRF relevant to NSCLC and its application | |
CN113122638B (en) | Application of hsa-novel_circ_0006787 molecule in liver cancer treatment | |
CN104774916B (en) | Biomarker combination used for detection of chemotherapy curative effect and/or prognosis of metastatic colorectal cancer and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200728 |